[PND18] Budget Impact Analysis of Fingolimod in Relapsing Remitting Multiple Sclerosis

[PND18] Budget Impact Analysis of Fingolimod in Relapsing Remitting Multiple Sclerosis

2014 ISPOR Europe

Ruggeri, M. | D'Ausilio, A. | Lo Muto, R. | Cottone, S. | Ghezzi, A. | Mecozzi, A. | Sacchini, D. | Mangone, M. | Volume: 17, Issue: 7, Pages: A393, analysis, budget impact, Value,

In recent years, fingolimod and natalizumab – though expensive – have brought significant improvements in second-line treatment of Multiple Sclerosis (MS). In Italy, fingolimod was acknowledged in 2011 the therapeutic innovation criterion which exempts the manufacturer from a mandatory discount of 5% on the ex-factory price for a three-year period. Since the innovation period is soon expiring and in order to assess the affordability of this therapy for the National and Regional Healthcare Systems (HSs), we performed a Budget Impact Analysis (BIA) of fingolimod in second-line treatment of MS, enclosed an ethical assessment of justice issues.

https://www.doi.org/10.1016/j.jval.2014.08.872; 10.1016/j.jval.2014.08.872